In glioma research, the increase of LOX protein expression is positively associated with the malignant grade of astrocytomas and GBM with IDH1 mutation always exhibits lower LOX expression levels (da Silva et al., 2015) compared with the wild type group. The gene discussed is LOX; the disease is astrocytoma (excluding glioblastoma).